Apogee Therapeutics partners with Paragon Therapeutics on IL-31R antibody discovery program

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE

0.00
  • Apogee Therapeutics entered an antibody discovery partnership with Paragon Therapeutics on June 17, 2026, targeting IL-31R.
  • Paragon will generate and characterize IL-31R antibody candidates; Apogee will pay a monthly research fee, cost reimbursements, optional CMC fees of $1.3 million-$2 million.
  • A related license grants Apogee exclusive worldwide rights to IL-31R antibodies, with Paragon retaining certain multispecific rights.
  • Paragon is eligible for up to $23.25 million in milestones, including $5.25 million at first Phase I patient dosing.
  • Paragon also earns low-single-digit royalties on net sales; royalty term runs at least 12 years from first commercial sale per country.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-025841), on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.